Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study

Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are widely prescribed in people with type 2 diabetes. We aimed to investigate whether SGLT2 inhibitor prescription is associated with COVID‐19, when compared with an active comparator. We performed a propensity‐score‐matched cohort study with active...

Descripción completa

Detalles Bibliográficos
Autores principales: Sainsbury, Christopher, Wang, Jingya, Gokhale, Krishna, Acosta‐Mena, Dionisio, Dhalla, Samir, Byne, Nathan, Chandan, Joht Singh, Anand, Astha, Cooper, Jennifer, Okoth, Kelvin, Subramanian, Anuradhaa, Bangash, Mansoor N., Taverner, Thomas, Hanif, Wasim, Ghosh, Sandip, Narendran, Parth, Cheng, Kar K., Marshall, Tom, Gkoutos, Georgios, Toulis, Konstantinos, Thomas, Neil, Tahrani, Abd, Adderley, Nicola J., Haroon, Shamil, Nirantharakumar, Krishnarajah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537530/
https://www.ncbi.nlm.nih.gov/pubmed/32991065
http://dx.doi.org/10.1111/dom.14203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537530/
https://www.ncbi.nlm.nih.gov/pubmed/32991065
http://dx.doi.org/10.1111/dom.14203

Ejemplares similares